Roche Wins UK NICE Backing for Tarceva in Advanced Lung Cancer

Roche’s Tarceva lung-cancer medicine won the backing of the UK’s health-cost agency after presenting data comparing the drug with AstraZeneca’s Iressa (gefitinib), which is already recommended.
Bloomberg